Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | EED | O75530 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281534 | 0.89 | CCR3 (0.49) | CCR3EEDSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL19049075 | 0.89 | CCR3 (0.51) | CCR3EEDSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL21169224 | 0.86 | CCR3 (0.47) | CCR3EEDSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL19002803 | 0.84 | CA1 (0.44) | CCR3ALDH1A1CA1CA2CA4 | |
| SCHEMBL13705102 | 0.84 | CCR3 (0.45) | CCR3EEDKDM4EALDH1A1CA1 | |
| SCHEMBL6132670 | 0.84 | CCR3 (0.45) | CCR3EEDKDM4EALDH1A1CA1 | |
| SCHEMBL19002804 | 0.83 | CA1 (0.58) | ALDH1A1CA1CA2CA4CA9 | |
| SCHEMBL19002465 | 0.80 | KRAS (0.47) | — | |
| Hydrochloric Acid SCHEMBL6133157 | 0.79 | RHOA (0.52) | CCR3ALDH1A1CA1CA2CA4 | |
| SCHEMBL23222258 | 0.78 | SLC6A4 (0.45) | EEDSIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CCR3 910/4885EED 2517/4885SIGMAR1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.